| Dr Thomas Michael Bickley, DO | |
|
4824 E Baseline Rd Ste 129, Mesa, AZ 85206-4679 | |
| (480) 644-1001 | |
| (480) 464-8722 |
| Full Name | Dr Thomas Michael Bickley |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 4824 E Baseline Rd Ste 129, Mesa, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639318991 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 006142 (Arizona) | Primary |
| Entity Name | Thomas M. Bickley, D.o., Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730422692 PECOS PAC ID: 4183863871 Enrollment ID: O20130610000165 |
News Archive
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced positive results from its phase IIa clinical trial assessing Dysport in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.
Children with migraine are more likely to have sleep disorders, such as sleep apnea and lack of sleep, than children without migraine, according to research on the effects of headaches on children's sleep patterns that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.
Boehringer Ingelheim today announced that data from its pivotal STARTVerso 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress 2013: 48th Annual Meeting of the European Association for the Study of the Liver, taking place from April 24-28 in Amsterdam, The Netherlands.
To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc., today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.
› Verified 8 days ago
| Entity Name | Women's Care Arizona, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942977624 PECOS PAC ID: 6103215322 Enrollment ID: O20211109003308 |
News Archive
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced positive results from its phase IIa clinical trial assessing Dysport in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.
Children with migraine are more likely to have sleep disorders, such as sleep apnea and lack of sleep, than children without migraine, according to research on the effects of headaches on children's sleep patterns that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.
Boehringer Ingelheim today announced that data from its pivotal STARTVerso 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress 2013: 48th Annual Meeting of the European Association for the Study of the Liver, taking place from April 24-28 in Amsterdam, The Netherlands.
To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc., today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Michael Bickley, DO Po Box 748860, Atlanta, GA 30374-8858 Ph: (480) 644-1001 | Dr Thomas Michael Bickley, DO 4824 E Baseline Rd Ste 129, Mesa, AZ 85206-4679 Ph: (480) 644-1001 |
News Archive
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced positive results from its phase IIa clinical trial assessing Dysport in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.
Children with migraine are more likely to have sleep disorders, such as sleep apnea and lack of sleep, than children without migraine, according to research on the effects of headaches on children's sleep patterns that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.
Boehringer Ingelheim today announced that data from its pivotal STARTVerso 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress 2013: 48th Annual Meeting of the European Association for the Study of the Liver, taking place from April 24-28 in Amsterdam, The Netherlands.
To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.
Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc., today announced that they have signed a Product Option License Agreement for BBI608 for all oncology indications in Japan and exclusive right of negotiation for BBI608 for the United States and Canada.
› Verified 8 days ago
Mrs. Eericca Michelle Bickley, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4824 E Baseline Rd Ste 129, Mesa, AZ 85206 Phone: 480-644-1001 Fax: 480-644-1002 | |
Gregory D Layton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4824 E Baseline Rd Ste 129, Mesa, AZ 85206 Phone: 480-644-1001 Fax: 480-464-8722 | |
Deanna Lynn Bullaro-anderer, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 5304 E Southern Ave, Ste 110, Mesa, AZ 85206 Phone: 480-237-3040 Fax: 480-237-3049 | |
Andrew R Adamson, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 455 E 6th St, Mesa, AZ 85203 Phone: 480-844-4702 | |
Marlin D. Mills, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1940 S Country Club Dr, Suite 102, Mesa, AZ 85210 Phone: 680-969-5999 Fax: 480-969-5610 | |
Dr. Carlos Alberto Mendez, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1705 W Main St, Mesa, AZ 85201 Phone: 877-809-5092 Fax: 480-840-1758 | |
Ronald C Burton, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1432 S Dobson Rd, Ste 509, Mesa, AZ 85202 Phone: 480-834-5111 Fax: 480-834-5222 |